CELLULAR therapyLEUCOCYTESBONE marrow cellsThis article discusses a case report on the use of bispecific CAR-T cell therapy in a patient with refractory myasthenia gravis (MG), an autoimmune neuromuscular disorder. The patient experienced sustained disappearance of symptoms and anti-acetylcholine receptor...
Cell, Volume 187, Issue 18, 5 September 2024, Pages 4826-4828 Daniel J. Baker, Carl H. June Highlights Summary Allogeneic chimeric antigen receptor (CAR)-T cells hold great promise for expanding the accessibility of CAR-T therapy, whereas the risks of allograft rejection have hampered its ap...
We also provide a comprehensive analysis of the use of CAR T cells in patients with B-ALL. In addition, we discuss the unique toxicities associated with this therapy and the management schemes that have been developed. 展开 关键词: Adoptive T-cell therapy B-cell acute lymphoblastic leukemia ...
CD19-targeted chimeric antigen receptor (CAR) T cell therapy induces remission in the majority of patients with relapsed and refractory (r/r) B-cell acute lymphoblastic leukemia (ALL), including those who have exhausted all other available salvage therapies [1,2,3]. While this novel therapy ha...
The study suggests that bispecific CAR-T cell therapy has the potential to be an effective treatment for MG and other diseases characterized by autoreactive B cells and autoantibodies.关键词: MYASTHENIA gravis RECEPTOR antibodies CELLULAR therapy LEUCOCYTES BONE marrow cells ...
Overall safety of CAR T Cell therapy in AID was very favourable with cytokine-release syndrome (CRS) of grade 0 in 4, grade 1 in 10, and grade 2 in 1 patient. 6/15 patients received tocilizumab. One grade 1 immune-effector cell associated neurotoxicity syndrome (ICANS) presented as vertig...
Allogeneic hematopoietic cell transplantation (allo-HCT) is offered to selected patients after chimeric antigen receptor–modified T-cell (CAR-T) therapy. Lymphodepleting chemotherapy and CAR-T therapy have immunosuppressive and immunomodulatory effects that could alter the safety profile of subsequent allo...
suggests that 4-1BB is more beneficial for the clinical performance of CAR-T cells than CD28 in CD19-targeted B-NHL therapy, at least under our manufacturing process. Keywords:B cell non-Hodgkin’s lymphoma; CD19-targeted chimeric antigen receptor-T cells; co-stimulatory domain....
suggests that 4-1BB is more beneficial for the clinical performance of CAR-T cells than CD28 in CD19-targeted B-NHL therapy, at least under our manufacturing process. Keywords:B cell non-Hodgkin’s lymphoma; CD19-targeted chimeric antigen receptor-T cells; co-stimulatory domain....
"The responses observed in these patients are very encouraging as we continue to evaluate the long-term efficacy of CAR NK cells in the treatment of these malignancies," said senior author Katy Rezvani, M.D., Ph.D., professor of Stem Cell Transplantation & Cellular Therapy. "In order to ...